These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27555788)

  • 21. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
    Baynes RD; Gansert J
    Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
    Hecht JR; Douillard JY; Schwartzberg L; Grothey A; Kopetz S; Rong A; Oliner KS; Sidhu R
    Cancer Treat Rev; 2015 Sep; 41(8):653-9. PubMed ID: 26220150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
    Perrone F; Lampis A; Orsenigo M; Di Bartolomeo M; Gevorgyan A; Losa M; Frattini M; Riva C; Andreola S; Bajetta E; Bertario L; Leo E; Pierotti MA; Pilotti S
    Ann Oncol; 2009 Jan; 20(1):84-90. PubMed ID: 18669866
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 28. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
    Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
    Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
    van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
    Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody.
    Adua D; Di Fabio F; Ercolani G; Fiorentino M; Gruppioni E; Altimari A; Rojas Limpe FL; Normanno N; Pinna AD; Pinto C
    Mol Clin Oncol; 2017 Jul; 7(1):113-120. PubMed ID: 28685087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All.
    Martins M; Mansinho A; Cruz-Duarte R; Martins SL; Costa L
    Adv Exp Med Biol; 2018; 1110():113-131. PubMed ID: 30623369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
    Khan SA; Zeng Z; Shia J; Paty PB
    Pathol Oncol Res; 2017 Jul; 23(3):673-677. PubMed ID: 28025786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
    Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing.
    Ashraf N; Kothari N; Kim R
    J Natl Compr Canc Netw; 2014 Oct; 12(10):1433-42. PubMed ID: 25313182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic mutations as predictive factors in colorectal cancer.
    Lièvre A; Blons H; Laurent-Puig P
    Oncogene; 2010 May; 29(21):3033-43. PubMed ID: 20383189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.